The FDA's review of BPC-157 for inclusion on the Section 503A Bulk Drug Substances List centers on longstanding safety concerns, including potential immunogenicity and peptide impurities, which previously placed it in Category 2. Removal from that restricted list occurred in April 2026, followed by a July 23-24 Pharmacy Compounding Advisory Committee meeting where the panel voted narrowly (8-6, one abstention) to recommend addition for ulcerative colitis use—overriding FDA staff opposition citing insufficient clinical data. This non-binding vote represents the most recent catalyst but leaves final agency action pending, with no confirmation of Category 1 placement as of mid-August 2026. Traders monitor timelines for FDA rulemaking or interim policy updates, as 503A eligibility would permit pharmacy compounding under prescription while remaining distinct from full drug approval.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयानया
31 अग, 2026
31 अगस्त, 2026
13%
31 दिसंबर, 2026
55%
$2,648 वॉल्यूम
31 अगस्त, 2026
$942 वॉल्यूम
13%
31 दिसंबर, 2026
$1,706 वॉल्यूम
55%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's review of BPC-157 for inclusion on the Section 503A Bulk Drug Substances List centers on longstanding safety concerns, including potential immunogenicity and peptide impurities, which previously placed it in Category 2. Removal from that restricted list occurred in April 2026, followed by a July 23-24 Pharmacy Compounding Advisory Committee meeting where the panel voted narrowly (8-6, one abstention) to recommend addition for ulcerative colitis use—overriding FDA staff opposition citing insufficient clinical data. This non-binding vote represents the most recent catalyst but leaves final agency action pending, with no confirmation of Category 1 placement as of mid-August 2026. Traders monitor timelines for FDA rulemaking or interim policy updates, as 503A eligibility would permit pharmacy compounding under prescription while remaining distinct from full drug approval.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
बाज़ार खुला: Jun 22, 2026, 10:10 PM ET
वॉल्यूम
$2,648समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's review of BPC-157 for inclusion on the Section 503A Bulk Drug Substances List centers on longstanding safety concerns, including potential immunogenicity and peptide impurities, which previously placed it in Category 2. Removal from that restricted list occurred in April 2026, followed by a July 23-24 Pharmacy Compounding Advisory Committee meeting where the panel voted narrowly (8-6, one abstention) to recommend addition for ulcerative colitis use—overriding FDA staff opposition citing insufficient clinical data. This non-binding vote represents the most recent catalyst but leaves final agency action pending, with no confirmation of Category 1 placement as of mid-August 2026. Traders monitor timelines for FDA rulemaking or interim policy updates, as 503A eligibility would permit pharmacy compounding under prescription while remaining distinct from full drug approval.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
वॉल्यूम
$2,648समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The FDA's review of BPC-157 for inclusion on the Section 503A Bulk Drug Substances List centers on longstanding safety concerns, including potential immunogenicity and peptide impurities, which previously placed it in Category 2. Removal from that restricted list occurred in April 2026, followed by a July 23-24 Pharmacy Compounding Advisory Committee meeting where the panel voted narrowly (8-6, one abstention) to recommend addition for ulcerative colitis use—overriding FDA staff opposition citing insufficient clinical data. This non-binding vote represents the most recent catalyst but leaves final agency action pending, with no confirmation of Category 1 placement as of mid-August 2026. Traders monitor timelines for FDA rulemaking or interim policy updates, as 503A eligibility would permit pharmacy compounding under prescription while remaining distinct from full drug approval.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न